stockportfolio.pro
Scholar Rock Holding Corporation (SRRK)
Healthcare · Biotechnology · NasdaqGS
Scholar Rock Holding Corporation revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $20.49M | $15.40M | $18.82M | $33.19M | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | $-25.00M | $-49.33M | $-51.00M | $-86.48M | $-131.80M | $-134.50M | $-165.79M | $-246.29M | $-377.94M |
| Net margin | — | — | -248.9% | -561.5% | -700.5% | -405.2% | — | — | — |
Source: Scholar Rock Holding Corporation SEC filings (10-K).
Explore 9 years of Scholar Rock Holding Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SRRK in your portfolio →
Scholar Rock Holding Corporation financial history by metric
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation — frequently asked questions
What is Scholar Rock Holding Corporation's revenue?
Scholar Rock Holding Corporation (SRRK) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Scholar Rock Holding Corporation profitable?
No — SRRK reported a net loss of $-377.94M in fiscal 2025.
What is SRRK's P/E ratio?
Scholar Rock Holding Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Scholar Rock Holding Corporation have?
As of fiscal year 2025, SRRK carried roughly $99.71M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Scholar Rock Holding Corporation's market cap?
Scholar Rock Holding Corporation (SRRK) has a market capitalization of about $5.32B, based on the latest data in our nightly-refreshed cache.
When does Scholar Rock Holding Corporation's fiscal year end?
SRRK's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Scholar Rock Holding Corporation's official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.